Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

2.4K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.4K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

893
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
893
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

325
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
325
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chimio-embolisation trans-artérielle des carcinomes hépatocellulaires par billes chargées à la doxorubicine. Transarterial chemoembolization of hepatocellular carcinoma with doxorubicin eluting beads.

Journal of medical imaging and radiation sciences·2019
Same author

Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.

Alimentary pharmacology & therapeutics·2018
Same author

Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis.

The British journal of dermatology·2017
Same author

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (<i>Observatoire dédié au Cancer Bretagne / Pays de la Loire</i>).

Oncologie (Paris, France)·2015
Same author

Ascitic fluid TREM-1 for the diagnosis of spontaneous bacterial peritonitis.

Gut·2015
Same author

Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study.

European journal of cancer (Oxford, England : 1990)·2015

Related Experiment Video

Updated: May 5, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K

Anti-inflammatory drugs and variceal bleeding: a case-control study

V De Lédinghen1, D Heresbach, O Fourdan

  • 1CHU, Poitiers, France.

Gut
|January 23, 1999
PubMed
Summary

Non-steroidal anti-inflammatory drugs (NSAIDs), particularly aspirin, significantly increase the risk of first-time esophageal variceal bleeding in cirrhotic patients. Healthcare providers should carefully consider this risk when prescribing NSAIDs to individuals with cirrhosis.

More Related Videos

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.2K

Related Experiment Videos

Last Updated: May 5, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K
Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.2K

Area of Science:

  • Gastroenterology
  • Hepatology
  • Clinical Pharmacology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with severe gastrointestinal complications, including peptic ulcer bleeding.
  • Acute bleeding from oesophageal varices is a critical and life-threatening complication in patients with cirrhosis of the liver.

Purpose of the Study:

  • To investigate the association between non-steroidal anti-inflammatory drug (NSAID) use and the occurrence of first-time bleeding episodes in cirrhotic patients with oesophageal or cardial varices.
  • To identify risk factors for variceal bleeding in patients with cirrhosis.

Main Methods:

  • A case-control study was conducted involving 125 cirrhotic patients who experienced bleeding related to oesophageal varices (cases) and 75 cirrhotic patients with oesophageal varices who had no prior bleeding history (controls).
  • Data on NSAID use, including aspirin, were collected via structured interviews.

Main Results:

  • Patients admitted for variceal bleeding were significantly more likely to have used NSAIDs in the week preceding the event (25%) compared to controls (11%), with an odds ratio of 2.8 (p=0.016).
  • Aspirin use, alone or with other NSAIDs, was more prevalent in cases (17%) than controls (4%), yielding an odds ratio of 4.9 (p=0.007).
  • Logistic regression identified NSAID use (OR=2.9) and variceal size (OR=4.0) as independent predictors of variceal bleeding risk.

Conclusions:

  • Aspirin, whether used alone or in combination with other NSAIDs, is associated with an increased risk of first-time variceal bleeding in patients with cirrhosis.
  • The potential benefits of aspirin therapy in cirrhotic patients must be carefully weighed against the demonstrated risk of variceal bleeding.
  • No definitive conclusions could be drawn regarding the independent risk associated with non-aspirin NSAIDs.